Study Name: DAPA ACT HF-TIMI 68
Principal: Erich Fruehling, MD in Grand Island
Selma Mohammed, MD in Omaha
Anuradha Tunuguntla, MD in Lincoln
Study Sites: CHI Health Clinic Heart Institute locations in Lincoln, Omaha, and Grand Island
Description: This is an international, multicenter, parallel-group, randomized, double-blind, placebo-controlled trial in patients with heart failure with reduced ejection fraction (left ventricular ejection fraction [LVEF] ≤40%) who have been stabilized during hospitalization for acute heart failure, evaluating the effect of in-hospital initiation of dapagliflozin versus placebo on the clinical outcome of cardiovascular death or worsening heart failure.